Steps taken following Prequalification of Lamivudine+Nevirapine+Zidovudine 150mg+200mg+300mg Tablets [*]

Changes	Product information affected	Accepted on
Change in the specification of the FPP	SmPC, PIL	18 February 2013
Addition of manufacturing site for the FPP	PIL	18 May 2013
Addition of quality control testing site for the FPP		04 October 2013
Change in the batch size of the FPP		19 December 2013
Addition of manufacturer for Lamivudine API		27 February 2014
Changes to the published information	WHOPAR parts affected	Accepted on
Change in the shelf-life of the FPP	4	24 July 2014
Change in the FPP primary packaging pack	3, 4	05 December 2016

[*] Trade names are not prequalified by WHO. This is under local drug regulatory authority's responsibility. Throughout this WHOPAR the proprietary name is given as an example only.